For a Suitably Profitable Study of Athalie (2)
Jean Rohou
Cairn.info 2003 DOI: 10.3917/inli.554.0011 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Palliative care patients with terminal illness experiencing depression, anxiety, and existential distress |
| Key findings | The authors propose that psychedelic-assisted psychotherapy, which combines preparation, substance intake, and integration of experiences, may produce rapid and long-lasting benefits for depression, anxiety, and existential distress in terminal illness, potentially offering remission where conventional approaches have shown little benefit, though methodological and administrative hurdles remain. |
Abstract
Depression, anxiety and existential distress associated with terminal illness have a major impact on quality of life among palliative care patients. Psychedelics are emerging as catalysts for reflective, introspective and sometimes spiritual exploration as part of psychotherapy, with potentially rapid and long-lasting multiple beneficial effects. Psychedelic-assisted psychotherapy (PAP) combines preparation, substance intake, and integration of experiences to facilitate profound psychospiritual change. Despite methodological and administrative hurdles, interest in this innovative approach continues to grow because of its potential to offer remission where conventional approaches have shown little benefits.